RNT consulting offers support in the development and commercialization of radiopharmaceuticals. We have unique expertise in alpha and beta emitting therapeutics and novel PET diagnostics agents. RNT consulting’s approach is customized for each situation to determine the best strategy to meet the client’s goals. We have extensive expertise throughout the product lifecycle from pre-clincal development to commercialization. What we offer • Planning and implementation of cGMP manufacturing facilities for radiopharmaceuticals • Development of Quality Managements Systems (QMS) for radiopharmaceuticals and APIs • Clinical development support • Regulatory advice, including radiation licensing • Raw Materials sourcing • Supply Chain consulting • Technology transfer of manufacturing and QC processes • Development of robust Quality Control procedures • Radiation safety advice • Bespoke training and education to clinical teams, sales teams, end users, prescribers and payers • Development of safety and handling concepts for radio-pharmaceuticals Our experience: RNT consulting has unique experience from 10 years of development of the first-in-class alpha emitting pharmaceutical radium-223 dichloride/Xofigo and working for a range of clients worldwide developing a range of theranostic products.